3^rd International Conference and Expo on Pharmaceutics & Novel Drug Delivery Systems April 11-12, 2024 Amsterdam, Netherlands

Roger M Leblanc received a BSc degree in Chemistry from University Laval in 1964, followed by a PhD in Physical Chemistry in 1968. Then, he obtained a Postdoc position at the Royal Institution of Great Britain for two years before moving to the University of Québec

Biophotophysics,Spectroscopy and Surface chemistry

Jorge González Borroto is a PhD (Specialist in Genetic Toxicology; Univ. Autónoma de Barcelona) and Bachelor of Pharmacy (Univ. Central de las Villas, Cuba). Current position: Senior Toxicologist & Nonclinical Safety Adviser, at Ferrer Advanced Biotherapeutics. Ferrer Internacional. Previous positions: Pharmacovigilance Officer/Senior Nonclinical Toxicologist (Ferrer); Medical Adviser. Dermatology Area (Ferrer); Senior Toxicologist. Head of In vivo Toxicology Group (Ferrer); Senior Nonclinical Toxicology Study Director (RCC-CIDA s.a.l.)

Nonclinical Toxicology,Safety Assessment and Pharmacovigilan

Prof. Dr. Christopher Brown, Ph.D., D.Sc., CC, AOE, FRS is a Full Professor and Academic Tenure of Chemistry at California South University (CSU), Irvine, California, USA. He is an American analytical and organic chemist, who pioneered a number of discoveries in the field of chemistry, his first and most famous being the synthesis of sucrose. His contributions include the discovery of the anomeric effect and the development of general methodologies for the synthesis of saccharides still employed in the area of Nucleic Acids Chemistry. He was a fellow of the American Chemical Society (ACS) and also the Royal Society of Chemistry (England), and a recipient of the prestigious Albert Einstein World Award of Science and Wolf Prize in Chemistry. Furthermore, he is currently Dean of the Faculty of Chemistry at California South University (CSU), Irvine, California, USA.

Discoveries in the field of chemistry, his first and most famous being the synthesis of sucrose and saccharides

Dr Zi (Sophia) Gu is a Lecturer and National Health and Medical Research Council (NHMRC) Early Career Fellow in the School of Chemical Engineering at University of New South Wales (UNSW), Sydney. She obtained PhD from Australian Institute for Bioengineering and Nanotechnology at The University of Queensland (UQ), Australia, in 2011, and she was awarded a NHMRC EC Fellowship in 2013 when she started her independent research at UQ prior to joining UNSW in 2016. Sophia has been working in multidisciplinary research areas that combine the knowledge and skills across nanotechnology and biomedicine, and has developed a targeted anti-restenotic therapy and built inorganic nanoparticle platforms for diagnosing and treating diseases. She published in high-impact journals including Advanced Materials, Biomaterials, Chemistry of Materials, Materials Horizons, and Journal of Controlled Release etc. Her recent awards include The Monash Engineering Women’s Leadership Award and Deputy Vice-Chancellor (Academic) Award. Her research group focuses on developing multifunctional nanomaterials for theranostic application (disease therapy and diagnosis

Nanoparticles for cancer treatment and diagnosis

Gautam Sethi has completed his Postdoctoral training at University of Texas MD Anderson Cancer Center and joined Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore in 2008 as an Assistant Professor and was promoted to Associate Professor in 2015. The focus of his research over the past few years has been to elucidate the mechanism(s) of activation of oncogenic transcription factors such as NF-kB/STAT3 by carcinogens and inflammatory agents and the identification of novel inhibitors of these proteins for prevention of and therapy for cancer. He has more than 150 scientific publications in high impact factor peer reviewed journals and has several international awards to his credit. He currently serves as an Academic Editor for PLOSONE, Editorial Board Member of Scientific Reports and ad-hoc Reviewer for several other international journals.

Drug Development,Pharmacology and Drug analysis

Dale W Laird and his research team has been examining the role of connexin gap junction proteins in health and disease for over 25 years. Since being recruited from McGill University in 1997, Dr. Laird’s research program has flourished as connexin gene mutations were discovered and shown to cause many human diseases. This coincided with the generation of numerous genetically-modified mice where connexin genes were ablated or mutated to mimic human diseases. Dr. Laird’s laboratory routinely employs these mutant mice together with organotypic cultures and patient cells to investigate the link between connexin gene mutations and a diverse array of diseases and syndromes ranging from skeletal development anomalies to skin disease.

Gap junction proteins, connexins, and a related family of channel proteins, pannexins, in health and disease

Dale W Laird and his research team has been examining the role of connexin gap junction proteins in health and disease for over 25 years. Since being recruited from McGill University in 1997, Dr. Laird’s research program has flourished as connexin gene mutations were discovered and shown to cause many human diseases. This coincided with the generation of numerous genetically-modified mice where connexin genes were ablated or mutated to mimic human diseases. Dr. Laird’s laboratory routinely employs these mutant mice together with organotypic cultures and patient cells to investigate the link between connexin gene mutations and a diverse array of diseases and syndromes ranging from skeletal development anomalies to skin disease.

Gap junction proteins, connexins, and a related family of channel proteins, pannexins, in health and disease